tbuckley/cabot-search huggingface dataset:
In Vivo Effects of Δ1-Testololactone on Peripheral Aromatization
Authors: Howard L. Judd, Robert M. Barone, Larry R. Laufer, Joseph C. Gambone, Steven L. Monfort, Bill L. Lasley
Journal: Cancer Research (1982)

To evaluate the in vivo effect of Δ1-testololactone on peripheral aromatization, studies were performed on seven postmenopausal women with metastatic breast cancer. Analysis of variance indicated that there were significant increases of circulating androstenedione ( p < 0.05) and estradiol ( p < 0.001) during administration of different doses of testololactone. Androstenedione levels were increased with all doses of testololactone tested (50, 100, 250, and 500 mg every 6 hr for 14 days each), while estradiol rose with only the 250- and 500- mg dosages. With administration, there was a significant decrease of estrone ( p < 0.001) with the mean level falling from 26 ± 3 (S.E.) to 11 ± 2 pg/ml. The addition of adrenal suppression (dexamethasone, 1 mg nightly at 11 p.m.) significantly lowered androstenedione ( p < 0.05) but had no effect on estrone or estradiol levels. Long-term therapy (up to 6 months) with the 250-mg dosage showed continual suppression of estrone with no escape being observed. Studies to determine the reason for the increase of estradiol with testololactone suggested cross-reactivity of the antibody with it in vivo metabolites of the drug. However, these possible metabolites did not bind to uterine cytosol estrogen receptors. The decrease in estrone with testololactone administration presumably explains its antitumor properties.
Abstract 15445: The Sirtuin SIRT3 Blocks Doxorubicin-induced Cardiac Hypertrophic Response of Mice
Authors: Vinodkumar Pillai, Sadhana Samant, Nagalingam Sundaresan, Gene Kim, Mahesh P Gupta
Journal: Circulation (2014)

Background and objective: Doxorubicin is a chemotherapeutic drug widely used to treat variety of cancers. One of the serious side effects of doxorubicin is its toxicity to the heart. Previously, we have shown that overexpression of SIRT3 blocks the hypertrophic response of the heart to agonist treatments. This study was undertaken to investigate whether SIRT3 can also attenuate the doxorubicin-induced cardiac hypertrophic response in mice. Methods and results: Neonatal rat cardiomyocytes overexpressed with SIRT3 and treated with doxorubicin (10μM) showed 28% reduced mean fluorescent intensity for CM-H 2 DCFDA dye, compared to mock infected control cells treated with doxorubicin, thus suggesting that SIRT3 was capable of blocking doxorubicin-induced ROS synthesis in cardiomyocytes. To examine the cardioprotective effects of SIRT3 in doxorubicin-induced cardiotoxicity in vivo ; we used a cumulative dose of 15mg/kg of doxorubicin for two different time points. One group of mice was treated intraperitoneally with 5mg/kg doxorubicin or an equal volume of saline every two weeks for a total of three doses. Transgenic mice having cardiac specific expression of SIRT3 (SIRT3-Tg) showed 33% reduced HW/BW ratio compared to control mice. Echocardiographic evaluation of hearts showed significantly reduced fractional shortening in control mice, compared to SIRT3-Tg mice (24.6 vs 34.7 %, P&lt;0.05). SIRT3-Tg mice also showed significantly reduced fetal gene expression for ANF, βMHC and collagen-1 as determined by RT-PCR. Masson’s trichrome staining showed significantly reduced fibrosis in doxorubicin treated SIRT3-Tg mice compared to its control. Furthermore, electron microscopic analysis showed preserved mitochondrial and sarcomeres structures in doxorubicin treated SIRT3-Tg hearts, whereas in wild-type hearts these structures were highly disorganized. Second group of mice that received 15mg/kg dose for two weeks also showed similar results. Contrary to this, whole body SIRT3 knockout mice showed exacerbated cardiac hypertrophic response compared to wild-type mice in response to doxorubicin treatment. Conclusion: These results demonstrated that SIRT3 is an endogenous negative regulator of doxorubicin-induced cardiac hypertrophic response.
Original article: Hepatocyte growth factor attenuates eotaxin and PGD<sub>2</sub>‐induced chemotaxis of human eosinophils
Authors: W. Ito, T. Chiba, A. Kanehiro, H. Kato, K. Yamaguchi, S. Ueki, H. Kayaba, J. Chihara
Journal: Allergy (2007)

Hepatocyte growth factor (HGF) is known to influence a number of cell types, and regulate various biologic activities including cell migration, proliferation, and survival. In a recent study, we found that, in vivo, HGF suppresses allergic airway inflammation, i.e. the infiltration of inflammatory cells including eosinophils into the airway, and further, that HGF reduces Th2 cytokine levels; however, the directly physiologic role of HGF with eosinophils remains unclear. In this study, we investigate the potential of recombinant HGF to regulate the factor-induced chemotaxis of human eosinophils.Eosinophils were isolated from subjects with mild eosinophilia by modified CD16-negative selection. After culture with or without recombinant HGF, esoinophil chemotaxis was measured by Boyden chamber and KK chamber.Treatment with HGF prevented eotaxin or prostaglandin D(2) (PGD(2))-induced chemotaxis of eosinophils. Moreover, we demonstrated that extracellular signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinases as well as the enhancement of Ca(2+) influx, which are indispensable for eosinophil chemotaxis, were attenuated by HGF treatment.Taken together, these data suggest that in allergic diseases, HGF not only mediates eosinophils through the inhibition of Th2 cytokines, but also regulates the function of eosinophils directly, provides further insight into the cellular and molecular pathogenesis of allergic reactions.
Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation
Authors: Nobuhiro Tsukada, Tetsuji Kobata, Yoshifusa Aizawa, Hideo Yagita, Ko Okumura
Journal: Blood (1999)
Abstract 14732: The Prognostic Implications of Right Bundle Branch Block in Healthy Population: a Systematic Review and Meta-analysis
Authors: Sunita Sharma, Ahmad Hazem, Amit Sharma, Cameron Leitch, Roopalakshmi Sharadanant, Matthew Uriell, Jason Henry, Kari Neutzling, Annie LeBlanc, Patricia Barrionuevo Moreno, Zhen Wang, Atsushi Sorita, Leonid Vilenski, Larry Prokop, Premraj Makkuni, Henry Ting, M Hassan Murad
Journal: Circulation (2014)

Objective: Multiple large population based observational studies have evaluated the association of various ECG changes with long term adverse outcomes demonstrating conflicting results regarding the significance of right bundle branch block (RBBB). Therefore, we conducted a systematic review and meta-analysis to determine the prognostic significance of RBBB in healthy population. Methods: This systematic review follows an a priori established protocol and is reported following the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). We systematically searched EMBASE, Web of Science and Scopus through January 2014. We also consulted with content experts to recommend studies for screening. Reviewers working independently and in duplicate screened all eligible abstracts, selecting randomized trials and prospective cohort studies that described all cause mortality or cardiovascular death in patients with RBBB. We excluded studies that reported unadjusted outcome or unadjusted event rates. For statistical analysis, hazard ratios were considered to approximate risk ratios. The main outcomes of the study are all-cause mortality and cardiovascular mortality. Results: Based on the eligibility, four large cohorts, with total patient count &gt; 100,000 were included in the meta-analysis. Risk of bias was assessed using the Newcastle-Ottawa scale and included studies were deemed to be of high quality. As demonstrated in Figure 1, RBBB was not associated increase in all-cause mortality (RR 1.05; 95% CI 0.89-1.25) or cardiovascular mortality (RR 1.09; 95% CI 0.70-1.69). Conclusion: In asymptomatic healthy patients, RBBB is not associated with poor outcome.
Effect of ursodeoxycholic acid treatment on alanine aminotransferase and γ-glutamyltranspeptidase serum levels in patients with hypertransaminasemia
Authors: S. Bellentani, G. Tabarroni, T. Barchi, I. Ferretti, N. Fratti, E. Villa, F. Manenti
Journal: Journal of Hepatology (1989)
Progression of Tricuspid Regurgitation After Repaired Functional Ischemic Mitral Regurgitation
Authors: Akira Matsunaga, Carlos M. G. Duran
Journal: Circulation (2005)

Despite correction of left-sided cardiac lesions, associated functional tricuspid regurgitation (TR) that was surgically ignored can persist. It can also appear de novo. The aim of this study was to analyze TR in a group of patients who underwent successful revascularization and mitral valve repair (MVRep) for functional ischemic mitral regurgitation (MR).Among 124 consecutive patients with MVRep, 70 left the operating room with MR < or =1+ and had a preoperative and follow-up transthoracic echocardiograph. Moderate or greater MR or TR was considered significant. Twenty-one patients (30%) had TR before surgery, and only 9 had TR repaired. The postoperative incidence of residual TR was not significantly different whether the tricuspid valve had been repaired (4 of 9 [44%]) or surgically ignored (8 of 12 [67%]). At last follow-up, 34 patients (49%) had significant TR. The incidence of TR increased from 25% at <1 year to 53% between 1 and 3 years and 74% at >3 years. Absence or presence of recurrent MR did not significantly affect TR (14 of 22 [64%] with MR versus 20 of 48 [42%] with no MR). Preoperative and postoperative tricuspid annulus size in patients with late TR was significantly larger than in patients without TR.Functional TR is frequently associated with functional ischemic MR. After MVRep, close to 50% of patients have TR. The incidence of postoperative TR increases with time. Preoperative tricuspid annulus dilation might be a predictor of late TR.
Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination
Authors: Nuno A. Fonseca, Ana S. Rodrigues, Paulo Rodrigues-Santos, Vera Alves, Ana C. Gregório, Ângela Valério-Fernandes, Lígia C. Gomes-da-Silva, Manuel Santos Rosa, Vera Moura, João Ramalho-Santos, Sérgio Simões, João Nuno Moreira
Journal: Biomaterials (2015)
Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis
Authors: Luis M. Martins, Peter W. Mesner, Timothy J. Kottke, Guriqbal S. Basi, Sukanto Sinha, Jay S. Tung, Phyllis A. Svingen, Benjamin J. Madden, Atsushi Takahashi, Daniel J. McCormick, William C. Earnshaw, Scott H. Kaufmann
Journal: Blood (1997)
Promise and pitfalls of prognostic models for epilepsy surgery—Authors' reply
Authors: Lara Jehi, Kevin Chagin, Ruta Yardi, Laura Tassi, Giorgio Lo Russo, Gregory Worrell, Fernando Cendes, Marcia Morita, Fabrice Bartolomei, Patrick Chauvel, Imad Najm, Jorge Gonzalez-Martinez, William Bingaman, Michael W Kattan
Journal: The Lancet Neurology (2015)
Abstract 16509: Young Long QT Syndrome Patients With KCNH2 Mutations Have Late Onset but Severe Symptoms
Authors: Junichi Ozawa, Seiko Ohno, Hideki Itoh, Takeru Makiyama, Minoru Horie
Journal: Circulation (2014)

Introduction: The long QT syndrome (LQTS) is one of the causes of sudden cardiac death in children. Although the risk factors for cardiac events depending on the genotype have been reported, age-related difference in phenotype remains unknown. Objectives: We aimed to clarify the age-and genotype-related clinical features in the young LQTS cohort (form 1 to 20y.o.). Methods and Results: This study comprised 101 symptomatic LQTS patients that were genotyped (male n=36, mean age 10.6±4.3). We excluded patients with multiple mutations. Fifty patients carried heterozygous mutations in KCNQ1, 48 in KCNH2 and 3 in SCN5A. LQTS-related cardiac events were classified into 3 categories; syncope, documented Torsades de pointes (TdP) and cardio-pulmonary arrest (CPA). Ninety patients experienced syncope, 7 were documented TdP and 4 suffered CPA. Figure shows a frequency histogram for the ages of first event in each genotype. The mean age of the onset in KCNH2 mutation carriers were significantly older (12.2±4.6y.o.) than those in KCNQ1 (9.2±3.5y.o., p&lt;0.001). The numbers and mean ages of the patients suffered CPA were 1 in KCNQ1 (12y.o.), 2 in KCNH2 (10.5±3.5y.o.) and 1 in SCN5A (6y.o.). TdP was significantly more frequently documented in the patients with KCNH2 mutations (n=6, 13.7±3.3y.o.) than those with KCNQ1 mutations (n=1, 9y.o., p=0.029). Conclusion: In the young LQTS patients, therefore, KCNH2 mutation carriers showed a severer phenotype than those of KCNQ1, though their age of onset was older. These finding helped us to choose more appropriate preventive therapy depend on the age of onset and genotype.
Review: IV iron does not increase serious adverse events compared with other forms of iron
Authors: Robert T. Means Jr
Journal: Annals of Internal Medicine (2015)

ACP Journal Club19 May 2015Review: IV iron does not increase serious adverse events compared with other forms of ironRobert T. Means Jr, MDRobert T. Means Jr, MDJames H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA (R.T.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2015-162-10-008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationAvni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90:12-23. https://pubmed.ncbi.nlm.nih.gov/25572192Clinical Impact RatingsGIM/FP/GP: Hematology: Nephrology: Oncology: Reference1. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol. 2008;83:580-8. [PMID: 18273906] Google Scholar Author, Article, and Disclosure InformationAffiliations: James H. Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA (R.T.M.)This article was published at Annals.org on 5 May 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 May 2015Volume 162, Issue 10Page: JC8KeywordsClinical trialsConfidence intervalsGastrointestinal infectionsHematology and oncologyNephrologySafetySucroseSystematic reviews ePublished: 19 May 2015 Issue Published: 19 May 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
MUSCULO-SPIRAL PARALYSIS AFTER SERUM INJECTION (RECURRING AFTER SECOND INJECTION)
Authors: Leopold Brahdy
Journal: Annals of Internal Medicine (1938)

Case Reports1 April 1938MUSCULO-SPIRAL PARALYSIS AFTER SERUM INJECTION (RECURRING AFTER SECOND INJECTION)LEOPOLD BRAHDYLEOPOLD BRAHDYSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-11-10-1911 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptL. D., a hospital orderly 25 years of age, was using alcohol in excess. He had never been in any occupation which could have exposed him to lead. On February 24, 1934, he was given 1500 units of tetanus anti-toxin because of a laceration of the sole of the foot. One week later, he complained of severe pain in the neck and in both arms. Examination showed the muscles of the arms tender and in some degree of spasm. The diagnosis of polyneuritis was made. On April 3, examination showed left wrist drop; no anesthesia. The wrist drop persisted several...References1. WILSONHADDEN GSB: Neuritis and multiple neuritis following serum therapy, Jr. Am. Med. Assoc., 1932, xciii, 123. CrossrefGoogle Scholar2. WULF F: Disorders of the nervous system after serum injection, Hospitalstidende, Copenhagen, 1933, lxxvi, 1237. Abstracted in Jr. Am. Med. Assoc., 1935, cii, 810. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication May 13, 1937. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySerum allergy 1 April 1938Volume 11, Issue 10Page: 1911-1912KeywordsAlcoholsAnesthesiaLacerationsMusclesParalysisTetanus ePublished: 1 December 2008 Issue Published: 1 April 1938 PDF downloadLoading ...
845. Enhanced Efficacy of Radiation Sensitivity by Controlled Gene Delivery of PTEN Expression Vector Conjugated with Cationized Gelatin in Prostate Cancer Cells
Authors: Ulrike Schillinger, Gabi Wexel, Christian Hacker, Martin Kullmer, Axel Stemberger, Christian Plank
Journal: Molecular Therapy (2004)

We have previously demonstrated the superiority of copolymer-protected gene vectors (COPROGs) over naked DNA and standard nonviral vectors in matrix-mediated gene delivery (Scherer et al. 2002, J. Gene Med. 4:634-643). Here we present a novel carrier formulation based on lyophilized fibrinogen-vector compositions. Upon rehydration and local mixing with thrombin, these preparations can be used as fibrin glues for the local in situ delivery of genes and nucleic acids, particularly of growth factor genes for tissue engineering. As fibrin is an excellent matrix for cell growth, the preparations can be formulated with cells to fill tissue defects such as cavities in cartilage or bone or to cover skin defects. Naked DNA is readily released from fibrin clots (70 % within 5 days) while COPROGs remain tightly immobilized in the fibrin matrix over extended periods of time with a linear release of 0.29 % per day. Naked DNA was essentially inactive in mediating gene delivery to primary cells including chondrocytes and keratinocytes incorporated in vector-loaded fibrin clots. COPROGs mediated efficient and sustained transfection resulting in transgene expression over at least three weeks. The transfection of the BMP-2 gene in chondrocytes enclosed in COPROG-loaded fibrin clots in vitro led to sustained BMP-2 expression and to the induction of alkaline phosphatase as well as to increased production of extracellular matrix. Sustained reporter gene expression was achieved in critical cartilage defects in rabbit knee joints filled with autologous chondrocyte-COPROG-fibrin glue composites. In conclusion, COPROG-loaded fibrinogen preparations used as gene-activated fibrin glue display a strong potential as injectable implants for tissue repair and also as growth factor producing matrices for tissue engineering.
Interferon‐gamma and IL‐10 may protect from allergic polysensitization in children: preliminary evidence
Authors: I. Prigione, F. Morandi, M. A. Tosca, M. Silvestri, V. Pistoia, G. Ciprandi, G. A. Rossi
Journal: Allergy (2009)

A functional defect of T regulatory cells (Treg) has been proposed as pathogenic mechanism of allergic reaction. Polysensitization is a common feature of allergic patients.It was to investigate the possible role of Treg-Th1 cytokines, in the development of new sensitizations in childhood.Forty monosensitized (MS) children with allergic rhinitis were evaluated and followed-up for 2 years. New sensitizations were investigated. IL-10 and IFN-gamma were evaluated in in vitro experiments.Children remaining MS showed significant higher production of both IL-10 and IFN-gamma.This preliminary study provided evidence that IL-10 and IFN-gamma production could be defective in allergic children prone to develop polysensitization.
A Handbook of Pathological Anatomy and Histology, with an introductory Section on Postmortem Examinations and the Methods of Preserving and Examining Diseased Tissues.
Authors: Francis Delafield, Theophil Mitchell Prudden
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract MP23: The Prognostic Value of 1,5-anhydroglucitol
Authors: Elizabeth Selvin, Andreea M Rawlings, Morgan Grams, James S Pankow, A. Richey Sharrett, Michael Steffes, Josef Coresh
Journal: Circulation (2014)

Background: 1,5-anhydroglucitol (1,5-AG) is inversely related to glucose excursions and is thought to be a useful indicator of short-term (1-2 week) hyperglycemia. A commercial assay for 1,5-AG is approved for use in the USA but the relationship of 1,5-AG to long-term outcomes is unclear. Methods: We measured 1,5-AG in stored serum samples from 11,106 participants in the ARIC Study without cardiovascular disease at baseline (1990-1992) and examined prospective associations with clinical outcomes. Cox models were adjusted for demographic, lifestyle, and clinical variables. Results: During 20 years of follow-up, there were 2,601 incident cases of diabetes (among the 10,344 persons without diabetes at baseline), 2,928 incident cases of cardiovascular disease, 1,328 incident cases of chronic kidney disease (among the 10,951 persons with normal kidney function at baseline) and 2,595 deaths. There were 137 prevalent cases of retinopathy (among 516 persons with diabetes) identified in 1993-1996 when retinal photographs were taken. Compared to persons with 1,5-AG concentrations ≥10 ug/mL and no history of diabetes, persons with diabetes and 1,5-AG &lt;6.0 ug/mL had significantly higher risks of chronic kidney disease (HR 4.45, 3.69-5.37), coronary heart disease (HR 3.81, 3.04-4.78), ischemic stroke (HR 3.84, 2.91-5.06), heart failure (HR 3.63, 3.01-4.38), and total mortality (HR 2.48, 2.12-2.91). Associations in persons with diabetes were attenuated but remained significant after adjustment for HbA1c. In persons with diabetes, 1,5-AG &lt;6.0 ug/mL was associated with a higher prevalence of retinopathy compared to persons with 1,5-AG ≥10 ug/mL (OR 12.90, 6.74-24.69). In persons without diabetes at baseline, 1,5-AG &lt;10 ug/mL was also associated with incident diabetes (HR 2.24, 1.97-2.54). Multivariable-adjusted spline models show the continuous associations of 1,5-AG with the prospective outcomes ( Figure ). Conclusions: 1,5-AG provides prognostic information regarding long-term risk of important clinical outcomes.